Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib in Advanced Solid Tumors with FGFR Alterations
NCT04083976Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 2 trial of erdafitinib in solid tumor (advanced stage), sponsored by Janssen Pharmaceutical. Started Nov 2019; status: completed.
02
Drugs
erdafitinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04083976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04083976.